Verve Q3, Pipeline Progress

 Seven participants across two cohorts dosed in the Heart-2 Phase 1b clinical trial of VERVE-102 targeting PCSK9; Initial data planned for the first half of 2025

First participant dosed in the Pulse-1 Phase 1b clinical trial of VERVE-201 targeting ANGPTL3; Regulatory clearances in Australia, Canada, and the U.K.

Cash, cash equivalents, and marketable securities of $539.9 million; cash runway through 2026

https://www.globenewswire.com/news-release/2024/11/05/2974785/0/en/Verve-Therapeutics-Announces-Pipeline-Progress-and-Reports-Third-Quarter-2024-Financial-Results.html